{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:02Z","timestamp":1740144182335,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["06\/403\/90"],"award-info":[{"award-number":["06\/403\/90"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40273-016-0396-x","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T11:50:15Z","timestamp":1457610615000},"page":"795-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial"],"prefix":"10.1007","volume":"34","author":[{"name":"For the Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Oddershede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Arenas-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas I.","family":"Paton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sculpher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"issue":"Suppl. 2","key":"396_CR1","first-page":"1","volume":"13","author":"I Williams","year":"2012","unstructured":"Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13(Suppl. 2):1\u201385.","journal-title":"HIV Med."},{"issue":"4","key":"396_CR2","first-page":"387","volume":"308","author":"MA Thompson","year":"2014","unstructured":"Thompson MA, Aberg JA, Hoy JF, Benson C, Gu HF, Hammer SM, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;308(4):387\u2013402.","journal-title":"JAMA."},{"issue":"7","key":"396_CR3","doi-asserted-by":"crossref","first-page":"e22003","DOI":"10.1371\/journal.pone.0022003","volume":"6","author":"S Mathis","year":"2011","unstructured":"Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6(7):e22003.","journal-title":"PLoS One."},{"issue":"3","key":"396_CR4","first-page":"247","volume":"37","author":"U Restelli","year":"2014","unstructured":"Restelli U, Croce D, Porazzi E, Scolari F, Bonfanti M, Galli M, et al. Health technology assessment in the HIV setting: the case of monotherapy. New Microbiol. 2014;37(3):247\u201361.","journal-title":"New Microbiol."},{"issue":"4","key":"396_CR5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11592220-000000000-00000","volume":"9","author":"B Gazzard","year":"2011","unstructured":"Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy. 2011;9(4):217\u201323.","journal-title":"Appl Health Econ Health Policy."},{"issue":"10","key":"396_CR6","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2352-3018(15)00176-9","volume":"2","author":"NI Paton","year":"2015","unstructured":"Paton NI, St\u00f6hr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV. 2015;2(10):e417\u201326.","journal-title":"Lancet HIV"},{"key":"396_CR7","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.","edition":"3"},{"key":"396_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2013."},{"key":"396_CR9","unstructured":"EuroQol Group. What is EQ-5D. 2013. http:\/\/www.euroqol.org\/faqs\/eq-5d-3l.html . Accessed 11 Jan 2016."},{"issue":"11","key":"396_CR10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care."},{"key":"396_CR11","unstructured":"British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. London: Pharmaceutical Press; 2013."},{"key":"396_CR12","volume-title":"Electronic Market Information Tool (eMit)","author":"Department of Health Commercial Medicines Unit","year":"2013","unstructured":"Department of Health Commercial Medicines Unit. Electronic Market Information Tool (eMit). Canterbury: Personal Social Services Research Unit; 2013."},{"key":"396_CR13","volume-title":"Unit costs of health and social care 2012","author":"L Curtis","year":"2012","unstructured":"Curtis L. Unit costs of health and social care 2012. Kent: Personal Social Services Research Unit, The University of Kent; 2012."},{"key":"396_CR14","unstructured":"National Health Service (NHS). NHS reference costs: financial year 2011 to 2012. 2012. http:\/\/cmu.dh.gov.uk\/electronic-market-information-tool-emit\/ . Accessed 6 June 2014."},{"key":"396_CR15","doi-asserted-by":"crossref","unstructured":"Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1\u2013503, v\u2013vi.","DOI":"10.3310\/hta19140"},{"issue":"1","key":"396_CR16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1198\/000313007X172556","volume":"61","author":"NJ Horton","year":"2007","unstructured":"Horton NJ, Kleinman KP. Much ado about nothing: a comparison of missing data methods and software to fit incomplete data regression models. Am Stat. 2007;61(1):79\u201390.","journal-title":"Am Stat."},{"issue":"3","key":"396_CR17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1536867X0400400301","volume":"4","author":"P Royston","year":"2004","unstructured":"Royston P. Multiple imputation of missing values. Stata J. 2004;4(3):227\u201341.","journal-title":"Stata J."},{"issue":"1","key":"396_CR18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.22237\/jmasm\/1367382480","volume":"12","author":"JEV Lloyd","year":"2013","unstructured":"Lloyd JEV, Obradovic J, Carpiano RM, Frosso M-S. Multiple imputation of missing multilevel, longitudinal data: a case when practical considerations trump best practices? J Mod Appl Stat Methods. 2013;12(1):261\u201375.","journal-title":"J Mod Appl Stat Methods."},{"issue":"3","key":"396_CR19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11121-007-0070-9","volume":"8","author":"JW Graham","year":"2007","unstructured":"Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci. 2007;8(3):206\u201313.","journal-title":"Prev Sci."},{"issue":"12","key":"396_CR20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","volume":"32","author":"R Faria","year":"2014","unstructured":"Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014;32(12):1157\u201370.","journal-title":"Pharmacoeconomics."},{"issue":"4","key":"396_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1258\/1355819042250249","volume":"9","author":"J Barber","year":"2004","unstructured":"Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9(4):197\u2013204.","journal-title":"J Health Serv Res Policy"},{"issue":"5","key":"396_CR22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hec.944","volume":"14","author":"A Manca","year":"2005","unstructured":"Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487\u201396.","journal-title":"Health Econ"},{"key":"396_CR23","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. 1st ed. New York: Oxford University Press; 2006.","edition":"1"},{"issue":"8","key":"396_CR24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779\u201387.","journal-title":"Health Econ."},{"issue":"8","key":"396_CR25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","volume":"28","author":"MT May","year":"2014","unstructured":"May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28(8):1193\u2013202.","journal-title":"AIDS"},{"key":"396_CR26","first-page":"1","volume":"343","author":"M May","year":"2011","unstructured":"May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) study. BMJ. 2011;343:1\u201311.","journal-title":"BMJ."},{"key":"396_CR27","unstructured":"Mills J, Knipe E. Historic and projected mortality data from the period and cohort life tables, 2012-based, UK, 1981\u20132062. 2013. http:\/\/www.ons.gov.uk\/ons\/dcp171778_345078.pdf . Accessed 11 Jan 2016."},{"issue":"6","key":"396_CR28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800\u20134.","journal-title":"Med Decis Making."},{"key":"396_CR29","doi-asserted-by":"crossref","unstructured":"Feeney ER, Chung RT, Yazdanpanah Y. Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015;10(5):323\u20139. http:\/\/journals.lww.com\/co-hivandaids\/Abstract\/2015\/09000\/Current_guidelines_and_prioritizing_treatment_of.6.aspx . Accessed 24 Aug 2015.","DOI":"10.1097\/COH.0000000000000178"},{"key":"396_CR30","doi-asserted-by":"crossref","unstructured":"The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795\u2013807. http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1506816 . Accessed 24 Aug 2015.","DOI":"10.1056\/NEJMoa1506816"},{"key":"396_CR31","unstructured":"Yin Z, Brown A, Hughes G, Nardone A, Gill ON, Delpech V. HIV in the United Kingdom: 2014 report. London; 2014. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/401662\/2014_PHE_HIV_annual_report_draft_Final_07-01-2015.pdf . Accessed 24 Aug 2015."},{"key":"396_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/hec.655","volume":"11","author":"BJO O\u2019Brien","year":"2002","unstructured":"O\u2019Brien BJO, Gertsen K, Willan AR, Faulkner LA. Is there a kink in consumers\u2019 threshold value for cost-effectiveness in health care? Health Econ. 2002;11:175\u201380.","journal-title":"Health Econ."},{"issue":"2","key":"396_CR33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","volume":"24","author":"JR Arribas","year":"2010","unstructured":"Arribas JR, Horban A, Gerstoft J, F\u00e4tkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/ml. AIDS. 2010;24(2):223\u201330.","journal-title":"AIDS."},{"issue":"9927","key":"396_CR34","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","volume":"383","author":"R Puls","year":"2014","unstructured":"Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet (London, England). 2014;383(9927):1474\u201382. http:\/\/ww.ncbi.nlm.nih.gov\/pubmed\/24522178 . Accessed 24 Aug 2015.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"396_CR35","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S2352-3018(14)70018-9","volume":"1","author":"A Miners","year":"2014","unstructured":"Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV. 2014;1(1):e32\u201340. http:\/\/ww.sciencedirect.com\/science\/article\/pii\/2352301814700189 . Accessed 6 Jan 2016.","journal-title":"Lancet HIV"},{"issue":"8","key":"396_CR36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00019053-200624080-00003","volume":"24","author":"DJ Clayson","year":"2006","unstructured":"Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. A comparative review of health-related quality-of-life measures for use in HIV\/AIDS clinical trials. Pharmacoeconomics. 2006;24(8):751\u201365. http:\/\/link.springer.com\/10.2165\/00019053-200624080-00003 . Accessed 6 Jan 2016.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-016-0396-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-016-0396-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T22:49:25Z","timestamp":1718405365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-016-0396-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1007\/s40273-016-0396-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}